Electra Therapeutics (ETRA) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Electra Therapeutics is the larger company by market cap ($574.9 million vs $550.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETRA | PHAT |
|---|---|---|
| Share price | $9.16 | $6.81 |
| Market cap | $574.95M | $550.94M |
| 1-day change | -6.72% | +0.44% |
| YTD return | — | -58.95% |
| 1-year return | — | -37.18% |
| 5-year return | — | -79.05% |
| Forward P/E | — | 6.33 |
| EPS (TTM) | $-2.65 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.50 | $18.31 |
| 52-week low | $8.92 | $6.52 |
| Distance from 52-week high | -40.90% | -62.81% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +200.29% |
| Average volume | 948.89K | 1.40M |
| Shares outstanding | 62.77M | 80.90M |
| Employees | 46 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Electra Therapeutics
ETRA stock →Electra Therapeutics, Inc. is a clinical-stage biotechnology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees
ETRA vs PHAT FAQ
Which is bigger, Electra Therapeutics or Phathom Pharmaceuticals?
Electra Therapeutics (ETRA) is larger, with a market capitalization of $574.95M compared with $550.94M for Phathom Pharmaceuticals (PHAT).
Are Electra Therapeutics and Phathom Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Electra Therapeutics and Biotechnology: Pharmaceutical Preparations for Phathom Pharmaceuticals.